Brief: Sino Biopharmaceutical Says LM-108 Included In Breakthrough Therapy Designation
26/06/2025 11:32
June 26 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: LM-108 INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CENTER FOR DRUG EVALUATION OF NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit